Korsana Biosciences, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, with an emphasis on Alzheimer’s disease. Founded in 2024 and headquartered in Waltham, Massachusetts, the company operates in the United States and is advancing its pipeline through its proprietary THETA-enabled antibody engineering approach. Its lead product candidate is KRSA-028, a next-generation, shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease; the program is designed to improve amyloid plaque clearance, limit amyloid-related imaging abnormalities and hematologic adverse events, and support low-volume subcutaneous administration. Korsana’s development efforts include preclinical and discovery-stage work around neurodegenerative disease therapeutics, and its work with KRSA-028 was originally discovered in partnership with Paragon Therapeutics, Inc. Korsana also offers a pipeline of potential best-in-class therapeutics for neurodegenerative disorders under its THETA platform. In February 2026, the company emerged from stealth with $175 million in funding, including a prior $150 million Series A financing and an earlier seed round, to accelerate development of KRSA-028 toward clinical testing. In September 2026, Korsana completed its merger with Cyclerion Therapeutics, Inc. and a previously announced $380 million private placement, creating the combined public company now trading on Nasdaq under the ticker KRSA. In August 2026, the company strengthened its leadership team with the appointments of a Chief Medical Officer, a Chief Technical Officer, and a new Board member as it prepared for the transaction and continued advancing its neurodegenerative disease pipeline.
Company News
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ)
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets